

Rachel B Salit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4340173/publications.pdf>

Version: 2024-02-01

18
papers

636
citations

1040056

9
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

1166
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of JAK inhibitors in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 857-865.	2.4	3
2	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101 Open for Accrual June 2012. <i>Open for Accrual June 2012. Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	1.2	4
3	Hematopoietic Cell Transplant for Myelofibrosis. , 2021, , 311-327.		0
4	Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 70-76.	2.4	39
5	Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1681-1683.	2.4	4
6	Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2197-2203.	2.0	12
7	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. <i>Blood Advances</i> , 2020, 4, 3302-3310.	5.2	11
8	Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1520-1526.	2.0	7
9	Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1371-1374.	2.0	9
10	Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 145-150.	2.0	28
11	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
12	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
13	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
14	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
15	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 654-658.	2.0	14
16	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	27.0	352
17	Outcomes of Cord Blood Transplantation as Salvage Therapy After Graft Failure or Relapse after Prior Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 339-343.	2.0	8
18	Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1023-1035.	2.2	6